An updated edition of the February 5, 2026, article.The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific breakthroughs. According to the American Cancer Society, the United States alone is projected to record approximately 2.1 million new cancer cases and more than 626,000 deaths in 2026. On a global scale, increasing exposure to lifestyle-related risk factors—such as smoking, obesity, and sedentary behavior— and de ...

Key Takeaways J&J advanced its pipeline in 2025 with key approvals across oncology and immunologyJNJ secured approvals for Inlexzoh, Imaavy and Icotyde, expanding treatment options and pipeline depthJNJ's new cancer drugs generated $3B in 2025, with more growth expected from launches in 2026Johnson & Johnson (JNJ) has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience. J&J rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones ...

Johnson & Johnson ( JNJ ) is a true Dividend King with more than 60 years of consecutive dividend growth. In this uncertain market, investing in a dividend juggernaut with above-inflation long-term growth is just the medicineI have been an investor for a number of years mainly focusing on dividend paying companies. I think dividends and, perhaps more importantly, the growth of them, are foundational for high risk-adjusted long term returns. My approach is therefore to focus on stocks that either pay stable ...

The Dow Jones Industrial Average (^DJI) was up 305.43 (+0.66%) points today, closing at 46,429.49. Dow Futures (YM=F) also signaled strength, rising 280.00 (+0.60%) points to reach 46,695.00. The primary driver for Wednesday’s market action was a better-than-expected Durable Goods report, which suggested that capital spending remains resilient despite elevated borrowing costs. This economic data sparked a rally in cyclical stocks, as investors gained confidence in a "soft landing" scenario for the U.S. econ ...

Turning 65 with $1 million saved puts you in a position most Americans will likely never reach, but hitting this number is only half the work. The more important question is what that $1 million actually produces every month for the next 25 to 30 years, and whether that income will keep pace with a life that keeps getting more expensive. Quick Read A $1 million portfolio at 65 generates $2,917 to $5,833 monthly depending on yield strategy, with conservative 3-4% yields producing roughly $2,917, balance ...

Key TakeawaysThe U.S. has delivered a 15-point ceasefire proposal to Iran via Pakistani officials, including provisions for sanctions relief, a nuclear rollback, and guaranteed access to the Strait of Hormuz.BlackRock (BLK) CEO Larry Fink warned that a spike in oil prices to $150 per barrel would trigger a global recession, as energy costs continue to pressure European economies.European equity markets rallied on hopes of a diplomatic breakthrough, with Germany’s DAX rising 1.5% and the STOXX 600 gaining 0. ...

Key Takeaways JNJ stock stayed above 50- and 200-day SMAs for 8 months, signaling sustained bullish momentum.J&'s growth is driven by Innovative Medicine strength, new drugs, and R&D and M&A spend.JNJ faces Stelara patent loss, China headwinds, and 74,000 talc lawsuits, impacting future outlook.Johnson & Johnson’s (JNJ) stock has remained firmly above its 50-day and 200-day simple moving averages (SMAs) for more than eight months, dating back to mid-July 2025, reflecting sustained investor confidence. Notab ...

Quick Read iShares U.S. Pharmaceuticals ETF (IHE) has 46.8% of its $1.1B portfolio concentrated in Johnson & Johnson (JNJ), up 14% year-to-date on strong DARZALEX sales of $3.90B, and Eli Lilly (LLY), down 15% year-to-date despite Mounjaro hitting $7.41B in Q4 2025 revenue. The fund itself is flat year-to-date, down 0.5%, reflecting opposing performance between its two dominant holdings facing pricing pressure and manufacturing constraints. The Trump administration’s aggressive drug pricing reform thro ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...

Last Wednesday , Johnson & Johnson ( JNJ ) announced that the FDA had approved Icotyde, a once-daily oral peptide for the treatment of plaque psoriasis. This drug selectively blocks the interleukin-23 receptor (IL-23) and was a joint discovery withBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employm ...